iQure Pharma, a clinical-stage biotech company developing a new therapeutic approach for CNS disorders by restoring glutamate homeostasis, announced on Monday that the United States Patent and Trademark Office (USPTO) has granted a US patent for its clinical-stage asset iQ-007.

The company says that iQ-007 is a first-in-class, orally available small molecule that enhances the activity of the main glutamate transporter EAAT2. The compound is currently in Phase 1 clinical development for treatment-resistant epilepsy, with expected completion in December 2025.

Welcoming the patent for iQ-007, Pawel Zolnierczyk, iQure Pharma CEO, said: "The US is one of the most important markets for new therapeutics.Importantly, the granted patent covers both composition of matter and medical use of iQ-007. This milestone strengthens the value of this promising new therapy, and we look forward to advancing its clinical development."